Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALaDIN - Low-dose interleukin-2 in autism spectrum disorders
2025-522841-23-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing ILT-101 low-dose interleukin-2 with Placebo of ILT-101 (2 arms). Planned start Nov 2025; status: authorised.
02
Drugs
aldesleukin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2025-522841-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522841-23-00.